Twelve-month clinical outcomes of everolimus-eluting stent as compared to paclitaxel- and sirolimus-eluting stent in patients undergoing percutaneous coronary interventions. A meta-analysis of randomized clinical trials

International Journal of Cardiology

Volumn 150, Issue 1, 2011, Pages 84-89

  Cassese, Salvatore ^a   Piccolo, Raffaele ^a   Galasso, Gennaro ^a   De Rosa, Roberta ^a   Piscione, Federico ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Everolimus eluting stent; Meta analysis; Paclitaxel eluting stent; Percutaneous coronary intervention; Sirolimus eluting stent

Indexed keywords

EVEROLIMUS; PACLITAXEL; RAPAMYCIN;

ADULT; AGED; ARTICLE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANGIOPLASTY, BALLOON, CORONARY; DRUG-ELUTING STENTS; HUMANS; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; TREATMENT OUTCOME;

EID: 79960040877     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.01.015     Document Type: Article

References (40)

1. J.W. Moses, M.B. Leon, and J.J. Popma Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery N Engl J Med 349 2003 1315 1323 (Pubitemid 37186209)
2. G.W. Stone, S.G. Ellis, and L. Cannon Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial JAMA 294 2005 1215 1223 (Pubitemid 41352109)
3. M. Joner, A.V. Finn, and A. Farb Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202 (Pubitemid 43929240)
4. A.V. Finn, G. Nakazawa, and M. Joner Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510 (Pubitemid 46986103)
5. H.M. van Beusekom, F. Saia, and J.D. Zindler Drug-eluting stents show delayed healing: paclitaxel more pronounced than sirolimus Eur Heart J 28 2007 974 979 (Pubitemid 47343915)
6. A. Farb, M. John, E. Acampado, F.D. Kolodgie, M.F. Prescott, and R. Virmani Oral everolimus inhibits in-stent neointimal growth Circulation 106 2002 2379 2384 (Pubitemid 35244741)
7. Y. Onuma, N. Kukreja, and N. Piazza The everolimus-eluting stent in real-world patients: 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) registry J Am Coll Cardiol 54 2009 269 276
8. K. Tsuchida, J.J. Piek, and F.J. Neumann One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial) EuroIntervention 1 2005 266 272
9. F. Piscione, R. Piccolo, S. Cassese, G. Galasso, and M. Chiariello Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials Catheter Cardiovasc Interv 74 2009 323 332
10. Piscione F, Piccolo R, Cassese S, et al. Effect of drug-eluting stents in patients with acute ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: a meta-analysis of randomised trials and an adjusted indirect comparison. EuroIntervention 2010;5:853-60.
11. Higgins JP GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from http://www.cochrane-handbook.org.
12. P. Juni, A. Witschi, R. Bloch, and M. Egger The hazards of scoring the quality of clinical trials for meta-analysis JAMA 282 1999 1054 1060 (Pubitemid 29436453)
13. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses BMJ 327 2003 557 560 (Pubitemid 37088507)
14. R.M. Harbord, M. Egger, and J.A. Sterne A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints Stat Med 25 2006 3443 3457 (Pubitemid 44575162)
15. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, and L. Rushton Comparison of two methods to detect publication bias in meta-analysis JAMA 295 2006 676 680 (Pubitemid 43209069)
16. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 2009 264 269 [W64]
17. P.N. Ruygrok, M. Desaga, and F. Van Den Branden One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study EuroIntervention 3 2007 315 320
18. G.W. Stone, M. Midei, and W. Newman Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial JAMA 299 2008 1903 1913 (Pubitemid 351574920)
19. R.A. Byrne, A. Kastrati, and S. Kufner Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial Eur Heart J 30 2009 2441 2449
20. Kedhi E, Joesoef KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.
21. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.
22. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
23. G.W. Stone for the SPIRIT IV Investigators A large-scale randomized comparison of everolimus-eluting and paclitaxel-eluting stents: one-year clinical outcomes from the SPIRIT IV trial Am J Cardiol 104 2009 XV [TCT 2009 Abstract Supplement]
24. G. Biondi-Zoccai, M. Lotrionte, and C. Moretti Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher) Minerva Cardioangiol 56 2008 55 65 (Pubitemid 351522712)
25. Seth A, Serruys PW, Lansky A, et al. A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis. EuroIntervention 2010;5:788-94.
26. Bartorelli AL, Serruys PW, Miquel-Hebert K, Yu S, Pierson W, Stone GW. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. Catheter Cardiovasc Interv 2010;76:60-66.
27. E. Nikolsky, A.J. Lansky, and K. Sudhir SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease Am Heart J 158 2009 520 526 [e2]
28. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N Engl J Med 2010;363:136-46.
29. M.S. Chen, J.M. John, D.P. Chew, D.S. Lee, S.G. Ellis, and D.L. Bhatt Bare metal stent restenosis is not a benign clinical entity Am Heart J 151 2006 1260 1264 (Pubitemid 43866610)
30. A. De Labriolle, L. Bonello, and G. Lemesle Clinical presentation and outcome of patients hospitalized for symptomatic in-stent restenosis treated by percutaneous coronary intervention: comparison between drug-eluting stents and bare-metal stents Arch Cardiovasc Dis 102 2009 209 217
31. F. Alfonso, J.M. Auge, and J. Zueco Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study J Am Coll Cardiol 46 2005 756 760 (Pubitemid 41224795)
32. M. Pfisterer, H.P. Brunner-La Rocca, and P.T. Buser Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents J Am Coll Cardiol 48 2006 2584 2591 (Pubitemid 44881238)
33. G.W. Stone, J.W. Moses, and S.G. Ellis Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008 (Pubitemid 46376800)
34. J. Kotani, M. Awata, and S. Nanto Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings J Am Coll Cardiol 47 2006 2108 2111
35. A.V. Finn, M. Joner, and G. Nakazawa Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441 (Pubitemid 46717966)
36. J. Daemen, P. Wenaweser, and K. Tsuchida Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
37. M. Joner, G. Nakazawa, and A.V. Finn Endothelial cell recovery between comparator polymer-based drug-eluting stents J Am Coll Cardiol 52 2008 333 342 (Pubitemid 352001347)
38. Garg S, Serruys PW, Miquel-Hebert K. Four year clinical follow up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial. Catheter Cardiovasc Interv. 2010.
39. G.W. Stone, M. Midei, and W. Newman Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial Circulation 119 2009 680 686
40. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2